Medical Marijuana, Inc. and AXIM Biotechnologies, Inc. have entered into a strategic alliance to research and develop applications for AXIM's patent covering water-soluble cannabinoids. The agreement centers on AXIM's U.S. Patent No. 11,542,226 B2, which addresses a fundamental limitation of traditional cannabinoids: their inability to dissolve in water, significantly impairing absorption by the body.
Under the terms of the agreement, AXIM assigned to Medical Marijuana, Inc. a fifty percent right, title, and economic interest in the patent and all associated intellectual property. This includes rights to existing and future patents, licensing, enforcement, and monetization proceeds, as well as claims for past infringement and accrued royalties. Medical Marijuana, Inc. paid $600,000 for this assignment through a secured promissory note.
Concurrently, the companies entered into a Consulting Agreement where AXIM will provide research and development services focused on developing commercial applications for the patent technology. The agreement has an initial term of one year expiring in January 2027, with Medical Marijuana, Inc. paying AXIM $62,500 per month for these services.
The patented technology represents a significant advancement in cannabinoid delivery. Through molecular engineering, the patent covers novel molecules that link cannabinoids to complementary compounds, improving delivery mechanisms and therapeutic effectiveness. The engineered polyfunctional cannabinoids are more than 300 times more water-soluble than natural cannabinoids, enabling significantly improved absorption and therapeutic delivery.
Dr. Timothy R. Scott, who returned as president of Medical Marijuana, Inc. in conjunction with the agreement, stated that the company has tremendous confidence in AXIM's ability to provide R&D support for developing commercialized uses of the patent technology. "The potential for developing enhanced administration of water soluble CBD and other cannabinoids for certain ailments and conditions is a major development for MJNA," Scott said.
Catalina Valencia, AXIM President, commented that the alliance presents both companies with the ability to accelerate uses of the patent technology. "The water solubility of CBD and other cannabinoids is a significant development for the improved administration and increased potency of cannabinoids," Valencia stated. "We believe that the Patent could result in the development of a drug or treatment, most likely in the form of sublingual administration, able to treat a variety of conditions including anxiety or seizures."
The technology offers several key advantages beyond improved solubility. The polyfunctional constructs are engineered to produce more potent responses and efficacy than individual cannabinoid molecules, potentially allowing for lower therapeutic doses while avoiding toxic side effects associated with higher concentrations. This expanded treatment potential addresses conditions where traditional lipophilic cannabinoids have demonstrated limited bioavailability.
Medical Marijuana, Inc. manufactures and distributes natural health, beauty and hemp-derived cannabidiol products via e-commerce, direct sales, retail and wholesale distribution channels worldwide. The company operates through subsidiaries including HempMeds®, which distributes CBD products directly in the US and through wholly owned subsidiaries internationally, primarily in Mexico and Brazil, and Kannaway®, its direct selling division that was the first cannabis-based direct selling company when it started in 2014.
The strategic alliance positions both companies to potentially capitalize on the growing cannabinoid market while addressing significant technological barriers that have limited therapeutic applications. The development of water-soluble cannabinoids could open new treatment avenues and delivery methods, potentially transforming how cannabinoid-based therapies are administered and absorbed by patients.
